Structuring Milestone Payouts in Phase 3 Oncology Drug Licensing Deals
Biotech founders often agree to back-weighted milestone schedules that leave them cash-starved during costly Phase 3 clinical trials. Here is how to negotiate upfront developmental tranches.
Amit KasliwalCEO & Founder, Dehurdle
March 26, 20234 min read
The Developmental Milestone Tranche Script
Recommended Spoken Script
"To ensure our Phase 3 trial enrollment meets the 18-month FDA timeline, we require a $45M upfront licensing payment and $30M upon First Patient Dosed. Back-weighting milestones solely to NDA approval forces unnecessary dilution and risks study pacing."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice biopharma licensing negotiations in Dehurdle.
Follow Dehurdle on Google
Add Dehurdle to your Google Preferred Sources to see our playbooks in your AI Overviews and Google Search.